News and Trends 15 Dec 2022
EMA gives Myrtelle’s Canavan disease gene therapy candidate OD designation
Myrtelle Inc., a clinical stage gene therapy company, has announced that the European Medicines Agency (EMA) has granted orphan drug (OD) designation for rAAV-Olig001-ASPA, the company’s lead gene therapy product…